FMP
DarioHealth Corp.
DRIO
NASDAQ
DarioHealth Corp. operates as a digital therapeutics company in the United States, Canada, the European Union, Australia, and New Zealand. The company offers Dario's metabolic solutions to address metabolic health needs, such as diabetes, hypertension, and weight management; Dario Musculoskeletal, which helps to prevent and treat the most common MSK conditions; Dario's behavioral health solution that optimizes access to evidence-based care; chronic condition management solutions; DarioEngage, a proprietary care management platform; and device-specific disposables test strip cartridges, lancets, and blood glucose monitoring systems. It also provides smart glucose meters; bluetooth connected blood pressure cuff; digital scales; biofeedback sensor devices; and diabetes management programs, including lifestyle changes, healthy eating, advanced tracking, and live coaching. The company was formerly known as LabStyle Innovations Corp. and changed its name to DarioHealth Corp. in July 2016. DarioHealth Corp. was incorporated in 2011 and is based in New York, New York.
0.75 USD
0.0499 (6.65%)
Historical Prices
From:
To:
About
ceo
Mr. Erez Raphael
sector
Healthcare
industry
Medical - Diagnostics & Research
website
https://www.mydario.comexchange
NASDAQ
Description
DarioHealth Corp. operates as a digital therapeutics company in the United States, Canada, the European Union, Australia, and New Zealand. The company offers Dario's metabolic solutions to address metabolic health needs, such as diabetes, hypertension, and weight management; Dario Musculoskeletal, which helps to prevent and treat the most common MSK conditions; Dario's behavioral health solution that optimizes access to evidence-based care; chronic condition management solutions; DarioEngage, a proprietary care management platform; and device-specific disposables test strip cartridges, lancets, and blood glucose monitoring systems. It also provides smart glucose meters; bluetooth connected b...
CIK
0001533998
ISIN
US23725P2092
CUSIP
23725P209
Address
18 West 18th Street
Phone
833 914 3796
Country
US
Employee
196
IPO Date
Mar 14, 2016
Financial Statement
Earnings
DRIO Financial Summary
CIK
0001533998
Exchange
NASDAQ
Industry
Medical - Diagnostic...
Sector
Healthcare
CUSIP
23725P209
ISIN
US23725P2092
Country
US
Price
0.75
Beta
1.56
Volume Avg.
305.66k
Market Cap
31.17M
Shares
-
52-Week
0.501-1.93
DCF
7.31
ROE
-
ROA
-
Operating Margin
-
Debt/Equity
-
P/E
-1.23
P/B
-
Website
https://www.mydario.com
Upgrades and Downgrades
We are unable to load the data!
Financial Information
Financial Summary Real-Time Price
Financial Statements
Financial Quarter Statements
Ratios Analysis
Dupont Analysis
Free Cashflow
Operating Data
Balance Sheet Data
Financial Modelling
Discounted Cashflow Model
Discounted Cashflow Model Levered
Free Cashflow Build-Up
Terminal Value
Intrinsic Value
Weighted Average Cost of Capital
Market Information
Stock Value
Latest DRIO News
Tony Dante
Mar 7, 2025
DarioHealth Corp. (NASDAQ:DRIO) Earnings Preview: A Deep Div...
DarioHealth Corp. (NASDAQ:DRIO) is a key player in the digital health sector, focusing on innovative solutions for chronic disease management. As the company prepares to release its quarterly earnings on March 10, 2025, Wall Street anticipates a loss of $0.16 per share. Revenue is projected to be around $7.39 million, reflecting the company's ongoing efforts in the competitive digital health market. The upcoming earnings call will be led by CEO Erez Raphael and Chief Commercial Officer Steven N...
Seeking Alpha
Aug 10, 2024
DarioHealth Corp. (DRIO) Q2 2024 Earnings Call Transcript
DarioHealth Corp. (NASDAQ:DRIO ) Q2 2024 Results Conference Call August 8, 2024 8:30 AM ET Company Participants Kat Parrella - Investor Relations Manager Erez Raphael - Chief Executive Officer Steven Nelson - Chief Commercial Officer Conference Call Participants Lucas Romanski - TD Cowen Operator Good morning, ladies and gentlemen, and welcome to the DarioHealth Second Quarter 2024 Results Conference Call. At this time, all lines are in a listen-only mode.
Zacks Investment Research
Aug 8, 2024
DarioHealth Corp. (DRIO) Q2 Earnings Beat Estimates
DarioHealth Corp. (DRIO) came out with quarterly earnings of $0.06 per share, beating the Zacks Consensus Estimate of a loss of $0.29 per share. This compares to loss of $0.58 per share a year ago.
PRNewsWire
Jul 30, 2024
DarioHealth to Report Second Quarter 2024 Results on Thursda...
Company to host conference call and webcast at 8:30am ET NEW YORK , July 30, 2024 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO), a leader in the global digital therapeutics (DTx) market, announced today that it will release its financial results for the 2nd quarter ended June 30th, 2024, on Thursday, August 8th, 2024, before the market opens and will host a conference call and webcast at 8:30 am Eastern Time. Erez Raphael, Chief Executive Officer, and Steven Nelson, Chief Commercial Officer, ...
InvestorPlace
Jun 25, 2024
3 Small-Cap AI Stocks to Buy Now: June 2024
While the innovation sphere constantly focuses on artificial intelligence these days, the top players in the field have gotten a lot of attention – maybe too much attention. Recently, we've seen the mighty Nvidia (NASDAQ: NVDA ) lose a step from its previously mercurial ways.
Zacks Investment Research
May 15, 2024
DarioHealth Corp. (DRIO) Reports Q1 Loss, Misses Revenue Est...
DarioHealth Corp. (DRIO) came out with a quarterly loss of $0.20 per share versus the Zacks Consensus Estimate of a loss of $0.59. This compares to earnings of $0.45 per share a year ago.
PRNewsWire
May 7, 2024
DarioHealth to Report First Quarter 2024 Results on Wednesda...
Company to host conference call and webcast at 8:30am ET NEW YORK , May 7, 2024 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO), a leader in the global digital therapeutics (DTx) market, announced today that it will release its financial results for the 1st quarter ended March 31st, 2024, on Wednesday, May 15th, 2024, before the market opens and will host a conference call and webcast at 8:30 am Eastern Time. Erez Raphael, Chief Executive Officer and Rick Anderson, President, will host the cal...
Seeking Alpha
Oct 3, 2023
DarioHealth Disappoints, But A Better Future Is Ahead
DarioHealth has experienced a disappointing year with stalled revenue growth and a decline in new customer wins. However, H2/23 and FY24 are expected to bring improved financials, including revenue growth, expanded gross margins, and declining operating expenses. The company's competitive advantages include a customer-friendly platform, a multi-condition platform, and partnerships with important industry players.
